Canada Markets closed


Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
0.0535+0.0045 (+9.18%)
At close: 05:35PM CEST

NOXXON Pharma N.V.

Max-Dohrn-Strasse 8-10
Berlin 10589
49 30 726247 0

Full Time Employees13

Key Executives

NameTitlePayExercisedYear Born
Dr. Aram Mangasarian Ph.D.CEO & Member of Management Board488.62kN/A1970
Mr. Bryan JenningsCFO & Member of Management BoardN/AN/AN/A
Dr. Jarl Ulf Jungnelius M.D., Ph.D.Sr. Medical Advisor, Chief Medical Officer & Member of Management BoardN/AN/A1951
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.

Corporate Governance

NOXXON Pharma N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.